Somatostatin Receptor Imaging-Guided Pasireotide Therapy in Medullary Thyroid Cancer With Ectopic Adrenocorticotropin Production

Frederik A. Verburg*, Martin Anlauf, Felix M. Mottaghy, Wolfram Karges

*Corresponding author for this work

Research output: Contribution to journalEditorialAcademicpeer-review


A 51-year-old man with a history of metastatic medullary thyroid cancer (MTC) presented with high adrenocorticotropin (ACTH) and urinary free cortisol levels. The diagnosis of ectopic ACTH production, a rare MTC complication, was established in this patient. PET/CT using the somatostatin analogue DOTA-(Tyr)-octreotate labeled with gallium (Ga-DOTATATE) was performed, showing positive radionuclide uptake in multiple MTC metastases. After this therapy with the novel somatostatin analogue, pasireotide was initiated after which urinary free cortisol and ACTH levels decreased. The present case thus illustrates a potential theranostic use of Ga-DOTATATE PET/CT in MTC.
Original languageEnglish
Pages (from-to)E83-E84
JournalClinical Nuclear Medicine
Issue number1
Publication statusPublished - Jan 2015


  • somatostatin receptor
  • Ga-68-DOTATATE
  • PET/CT
  • pasireotide

Cite this